Yahoo
Oslo - Delayed Quote NOK

Oncoinvent ASA (ONCIN.OL)

65.40 -3.60 (-5.22%)
At close: 4:25:12 PM GMT+1
Chart Range Bar
Loading chart for ONCIN.OL
  • Previous Close 69.00
  • Open 69.00
  • Bid 65.20 x --
  • Ask 66.80 x --
  • Day's Range 65.20 - 69.00
  • 52 Week Range 40.10 - 144.00
  • Volume 24,200
  • Avg. Volume 39,756
  • Market Cap (intraday) 400.798M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -83.20
  • Earnings Date Aug 27, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 110.00

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.

www.oncoinvent.com

42

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

ONCIN.OL
33.20%
MSCI WORLD (^990100-USD-STRD)
9.09%

1-Year Return

ONCIN.OL
14.24%
MSCI WORLD (^990100-USD-STRD)
10.77%

3-Year Return

ONCIN.OL
94.83%
MSCI WORLD (^990100-USD-STRD)
73.85%

5-Year Return

ONCIN.OL
99.94%
MSCI WORLD (^990100-USD-STRD)
52.43%

Analyst Insights

View More

Analyst Price Targets

110.00
110.00 Average
65.40 Current
110.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -94.22%

  • Return on Equity (ttm)

    -228.06%

  • Revenue (ttm)

    24.31M

  • Net Income Avi to Common (ttm)

    -171.16M

  • Diluted EPS (ttm)

    -83.20

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    106.77M

  • Total Debt/Equity (mrq)

    2.53%

  • Levered Free Cash Flow (ttm)

    -81.91M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: